** Biotech firm Aligos Therapeutics'ALGS.O shares fall 17.3% to $10.70, hit three-month low

** Company posts quarterly net loss of $13.08 per share vs loss of $5.50 per share a year earlier

** Reports cash equivalents and investments in 2024 of $56.9 million vs $135.7 million in 2023, which will provide sufficient funding of planned operations into H2 2026

** Company says it is continuing to evaluate a variety of options to fund continued development of its liver disease drug, including potential out-licensing

** As of last close, ALGS has fallen 44.3% in the past 12 months

(Reporting by Siddhi Mahatole)

((siddhi.mahatole@thomsonreuters.com))